RG2133 (2',3',5'-tri-O-acetyluridine)
Phase 1Small molecule
RG2133 (2',3',5'-tri-O-acetyluridine) is one of 12 small molecule programs targeting Mitochondrial Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Mitochondrial Disease
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Depakote
AbbVieApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Procysbi
HHorizon Therapeutics Ireland DAC
Phase 2
Vatiquinone
PPTC Therapeutics
Phase 3
Coenzymeq10
TTanta University
Phase 3
Sonlicromanol
KKhondrion BV
Phase 3
OMT-28
OOmeicos Therapeutics GmbH
Phase 2
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRepligen Corporation